TCM
PRTK

Tekla Capital Management’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

Tekla Capital Management’s Portfolio PRTK Stock Details PRTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-533,000
Closed -$12.8M – 162
2017
Q2 		$12.8M Sell
533,000
-229,581
-30% -$5.08M 0.48% 50
2017
Q1 		$14.7M Hold
762,581
– – 0.57% 38
2016
Q4 		$11.7M Hold
762,581
– – 0.5% 47
2016
Q3 		$9.92M Hold
762,581
– – 0.38% 60
2016
Q2 		$10.6M Hold
762,581
– – 0.44% 58
2016
Q1 		$11.6M Hold
762,581
– – 0.49% 51
2015
Q4 		$14.5M Hold
762,581
– – 0.52% 40
2015
Q3 		$14.5M Buy
762,581
+71,581
+10% +$1.78M 0.55% 40
2015
Q2 		$17.8M Buy
+691,000
New +$19.6M 0.66% 34

Other funds holding PRTK

OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.3B AUM 33.54% 1-Year Est. Return
ECP
Empyrean Capital Partners Los Angeles, California $3B AUM 34.24% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.6B AUM 47.77% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.66B AUM 11.67% 1-Year Est. Return